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The aim of this work was to determine whether conjugation of cultivated choroidal
melanoma and Burkitt’s lymphoma cells with gold nanoparticles (GNPs) is beneﬁcial
for these series of ocular cancer patients. GNPs are radiosensitizers and can sensi-
tize tumors to radiotherapy.This application has been examined in several tumor
types, but not in choroidal melanoma. This study shows the results of in vitro study
on the choroidal melanoma and also Burkitt’s lymphoma cells in the presence of
GNPs during continuous gamma irradiation. Cytotoxicity of GNPs were assessed for
ﬁve different concentrations then cultured melanoma and Burkitt’s lymphoma cells
were irradiated with a Gamma source in the presence and absence of NPs. Incuba-
tion of melanoma cells with GNP concentrations below 100 lg/ml, accompanied by
gamma irradiation, increased cell death (P value = 0.016) . In the absence of irradia-
tion, GNPs at these concentrations did not affect cultured melanoma cell metabo-
lism. Reduced cell viability resulted from a signiﬁcant increase in absorbed energy
by the tumor. Moreover, GNP concentrations higher than 200 lg/ml induced cyto-
toxicity in melanoma cells. Cytotoxicity assay in GNPs-loaded Burkitt’s lymphoma
cells showed a slight decrease in cell viability at 50 lg/ml and clear cytotoxicity at
concentrations higher than 100 lg/ml (P value = 0.035). Concentration and proper
injection doses of GNPs in sensitive tissues such as the human eye are important
variables yet to be determined.This is the ﬁrst report of choroidal melanoma
dosimetry performed in the presence of GNPs and provides valuable insights into
future therapeutic approaches. Further in vitro study with more different sizes and
concentrations is needed to determine the optimum size and concentration before
any clinical research in this regard.
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1 | INTRODUCTION
Choroidal melanoma1 is the most common eye cancer which origi-
nating from melanin-containing cells and has the highest rate of
metastasis among intraocular tumors.2–5 The most common method
of treatment for choroidal melanoma is radiation therapy.6 Experi-
mental and Monte Carlo (MC) studies have investigated the dosime-
try of choroidal melanoma using different radiotherapy sources.7–9
In radiation therapy, X and gamma rays, and beta and alpha parti-
cles can be emitted from radiation device such as linear accelerators,
sealed radioactive sources, or from radiolabeled substances. Plaque
brachytherapy is the most widely applied technique for choroidal
melanoma radiotherapy. Radioactive plaques are placed on the exte-
rior of the tumor to deliver high-dose radiation to the tumor while
reducing radiation exposure in surrounding healthy tissues.10–12
However, healthy and tumor tissues follow the same speciﬁc algo-
rithm of radiation dose absorption, which is a regular obstacle in the
treatment of eye tumors.
Gold nanoparticles (NPs) have strong photoelectric absorption
owing to their high atomic number and electron density, making
them potential radiosensitizer. Secondary electrons and Auger elec-
trons caused by gamma or x-ray irradiation can produce very high
local ionization density.13 Increasing the irradiation dose absorbed by
the tumor reduces treatment time. Given that the tumor and nearby
healthy tissues follow the same energy absorbance pattern, reduce
treatment time lower the irradiation dose absorbed by healthy tis-
sues and results in reduced adverse effects. However, if the NPs
penetrate to the surrounding normal cells, the absorbed dose by
these healthy cells will increase and this method does not beneﬁt
the ocular cancer patient. Our previous work demonstrated the
proper distribution of GNPs within the eye tumor and showed that
GNPs were not observed in extratumoral areas.14
Previously, it has been shown that loading gold NPs into pros-
tate, skin melanoma, and liver tumors, which are later exposed to
irradiation, results in greater dose absorption within the tumor than
the surrounding tissues.15–18
In recent MC studies,19,20 the effects of GNPs on the
brachytherapy for choroidal melanoma, have been investigated using
iodine (125I) and palladium (103Pd), the most common irradiation
sources for this type of intraocular tumor. These simulations were
performed with the eye model phantom and the water phantom to
determine the dose enhancement factor (DEF) in the presence and
in the absence of GNPs using the mentioned brachytherapy sources.
In addition, the signiﬁcance of the eye model on the DEF calculation
was evaluated by comparing the dosimetry calculations in the pres-
ence of GNPs in both eye model phantom and water phantom.
These simulations were done using the MCNP5 MC code and
reported the absorbed dose enhancement by choroidal melanoma
tumors for the mentioned sources. In fact the use of such
brachytherapy sources along with GNPs would yield a higher DEF in
the tumor site of the eye melanoma.
We performed an in vitro study on human choroidal melanoma
and Burkitt’s lymphoma cells and the comparison was made between
them. To the best of our knowledge, this is the ﬁrst time that chor-
oidal melanoma dosimetry has been performed with experimental
methods in the presence of GNPs.
In vitro analysis of the toxicity, radiosensitivity and the death of
cells was performed by multiple MTT and cell death assay.21,22 In the
in vitro phase, cultured melanoma cells were incubated with GNPs and
were irradiated with Gamma source to observe the induced effects of
the radioactive source through measuring cell death. Cytotoxicity and
optimum GNP concentrations were examined using ﬁve different GNP
concentrations. The same analysis was performed on Burkitt’s
lymphoma cells using MTT assay. Furthermore, the response to radia-
tion of GNP-loaded lymphoma and choroidal melanoma cells were
studied through with cell death assay and compared.
2 | METHODS
2.A | Nanoparticle synthesis
Gold NPs were synthesized following the FERN method23 by
employing chloroauric acid (HAuCl4-gold halides) (Merck, Darmstadt,
Germany), which was then reduced by sodium citrate. HAuCl4 com-
pound was dissolved in an adequate volume of water, to obtain the
desired 0.2145 M solution. The noted substance was heated, and a
1.26544 M sodium citrate was added.
The size of the resultant NPs can be controlled by the amount
of added citrate. In this reaction, citrate is used to convert Au (III) to
Au (I), and create the NPs. By shifting some factors such as tempera-
ture, and the ratio of the administered compounds, it is possible to
control both the size, and the distribution of the NPs.24–26
Transmission electron microscopy (TEM) was used to evaluate
the morphology and size of synthesized gold NPs using a Zeiss-
EM10C-80 KV electron microscope (Oberkochen, Germany) (Fig. 1).
The size of gold NPs was determined by measuring the diameter of
whole particles on the TEM image. The average size of these NPs
was in the range of 50 nm and most were spherical in shape.
Absorption spectra and absorbance measurements were obtained
with a PerkinElmer UV-visible spectrophotometer model Lambda 25
(Waltham, MA, USA) (Fig. 2). The absorbance measurement was
made over the wavelength range of 200–700 nm using 3 ml SUPRA-
SIL UV Quartz cells. A digital pH meter, model 632, Metrohm (Heri-
sau, Switzerland), with a combined glass electrode was used for pH
measurements.
2.B | Cell culture and cytotoxicity assay
Melanoma cells were extracted from a middle-aged human female
who underwent enucleation for a very advanced malignant choroidal
melanoma. Patient was a 62-year-old female with a clinical diagnosis
of large choroidal tumor with no history of brachytherapy and suspi-
cious to extras clearly extension of the tumor.
Histopathologic examinations disclosed an epithelioid type chor-
oidal melanoma with extrascleral extension. Immediately after enu-
cleation, the tumor tissue was obtained and digested with 1.25%
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trypsin and cultivated in Dulbecco’s modiﬁed Eagle’s medium F12 in
a T75 ﬂask with 20% fetal bovine serum (FBS). Cells were incubated
at 37°C in a 5% CO2 atmosphere.
Immunocytochemistry for Melan-A monoclonal antibody, as a
melanoma marker, was performed to identify melanoma cells. Mela-
noma cells were incubated with mouse anti-human Melan-A anti-
body (M7196; Dako, Glostrup, Denmark) for 24 h at 4°C.
Fluorescein isothiocyanate (FITC)-conjugated antibody (goat-anti-
mouse IgG; Santa Cruz, Carlsbad, CA, USA) was used for 45 min to
detect the immunoreactivity of cultivated melanoma cells to the
Melan-A. All experiments were performed in duplicate. Cells were
incubated with 4, 6-diamidino-2-phenyindole dihydrochloride (DAPI;
1.5 mg/ml; Santa Cruz) for 10 min, and immunoreactive cells were
observed by using an inverted microscope (Olympus IX71; Olympus
Corporation, Tokyo, Japan) equipped with a 460 nm ﬁlter for DAPI
and a 520 nm ﬁlter for FITC-conjugated antibodies (Fig. 3).
At passage 5, melanoma cells (in the culture medium) were dis-
pensed into 24-well tissue culture plates (1 ml containing 27 9 105
per well). GNPs (1 ml) were added to each well with concentrations
of 50–600 lg/ml. One well did not receive any GNPs, and was the
control. Different concentrations (50, 100, 200, 400, or 600 lg/ml)
of GNPs were added to the other ﬁve wells. Figure 4 shows a con-
focal microscopy image of GNPs-loaded melanoma cells taken 24 h
after the addition of GNPs and showing that the GNPs were clus-
tered in the cytoplasm.
Ramos cells (Burkitt’s lymphoma-derived cell line) were cultured in
Roswell Park Memorial Institute 1640 medium supplemented with 10%
FBS, 100 U/ml penicillin, 100 lg/ml streptomycin, and 0.05% L-gluta-
mine serum in a T75 ﬂask. Cells were dispensed into 24-well tissue cul-
ture plates (1 ml containing 2 9 105 cell per well) and incubated at
37°C with 5% CO2. GNPs were added to the cells as detailed above.
Cytotoxicity induced by different concentrations of GNPs was
measured using a multiple MTT assay test (a quantitative colorimet-
ric method to determine cytotoxicity) in a multiwell plate. Cell viabil-
ity, expressed as percentage relative to the untreated control (100%
cell viability), was measured in triplicate.
2.C | Irradiation
Melanoma tumor or Burkitt’s lymphoma cells were cultured in four
24-well tissue culture plates and 50, 100, 200, 400, or 600 lg/ml
GNPs were added,;this experiment was performed in triplicate. The
ﬁrst wells in all four plates were the control samples and irradiated
in the absence of NPs.
The plates were exposed to 30 Gy radiation using a Cobalt 60
machine, producing two gamma rays with energies of 1.17 and
1.33 MeV (Theratron 780; Phoenix Company, Ottawa, Canada). Cells
were placed on Plexiglas (5 mm thick) in the center of the
30 9 30 cm2 ﬁeld 80 cm from the irradiator so that the beam was
homogenized.
The cells were then stored for 24, 72, and 168 h, before cell
death was assessed. For apoptosis detection, a Cell Death Plus
ELISA kit was used according to the manufacturer’s instructions
(Roche Molecular Biochemicals, Indianapolis, IN, USA). The experi-
ment was repeated two more times with the same conditions except
that cells were irradiated with doses of 10 and 20 Gy.
3 | RESULTS
Melanoma cells were exposed to 50, 100, 200, 400, or 600 lg/ml
GNPs and cell viability was measured and compared to evaluate the
(a) (b)
F I G . 1 . Transmission electron
microscopy images of synthesized gold
nanoparticles with average size of 50 nm.
(a) Bar indicated 200 nm and (b) bar
indicated 50 nm.
F I G . 2 . The UV-visible absorption spectra of 50 nm GNPs; the
maximum absorbance intensity of nanoparticles was in wavelength
of around 532 nm.
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cytotoxicity of the gold NPs (P value = 0.035) (Fig. 5). The highest
concentration of GNPs that could be incubated with the cells, with-
out causing visible damage to the cells, was determined in this ﬁg-
ure.
The cytotoxicity induced in melanoma cells by different concen-
trations of GNPs was compared with that observed in Burkitt’s lym-
phoma cells 3 days after the introduction of GNPs (Fig. 6).
We compared ﬁve different GNP concentrations in melanoma
and Burkitt’s lymphoma cells. Some concentrations resulted in a 50%
or greater level of cell death in both kinds of cancer cells. While
such concentrations cannot be used in a clinical radiation setting, the
present work is a nonclinical primary study to investigate the behav-
ior of GNP-smeared cells that are exposed to radiation. Therefore,
such concentrations could provide useful information about the use
of GNPs in treating and targeting tumors and were used in the radia-
tion phase of this study. Using this approach, we could identify the
extent to which the death of eye melanoma cells in the absence of
radiation could affect, or decrease, the viability of the cells when
exposed to gamma radiation. Therefore, these results provide an
assessment of cell death and allow us to investigate the energy
absorbed by the tumor in proportion to the concentration of GNPs.
These results physically report the increase of the energy released
inside the cell for the higher concentrations of GNPs used. While
the use of high GNP concentrations are not clinically relevant, they
have been used in this study to provide invaluable information about
how irradiation and GNPs interact to improve tumor targeting efﬁ-
ciency in cancer cells.
Melanoma cells that had been loaded with different concentra-
tions of GNPs were irradiated with 30 Gy and the radiation-induced
apoptosis was quantiﬁed (Fig. 7) (P value = 0.016). We also applied
two radiation doses of 10 and 20 Gy and the cell death was assayed
24 h after irradiation. The decreases of about 9% and 14% in cell
viability were observed for melanoma cells in radiation doses of 10
and 20 Gy, respectively. Also a <20% decrease in cell viability was
observed for lymphoma cells in these radiation doses. In comparison
with the control sample, no signiﬁcant differences in apoptosis were
observed.
Apoptotic response of GNPs-loaded (50, 100, and 200 lg/ml)
melanoma and Burkitt’s lymphoma cells to irradiation was compared
on the seventh day after 30 Gy irradiation (Fig. 8).
4 | DISCUSSION
Regarding the results of our experimental study (Fig. 7), the amount
of increase observed in the number of dead melanoma cells
irradiated in the presence of GNPs, compared to the amount of irra-
diated dead cells in the absence of GNPs can demonstrate the
changes in absorbed energy.
It should be noted that factors including the number of cultured
cells in a laboratory environment, the precise concentration of GNPs,
(a) (b)
(c) (d)
F I G . 3 . Representative cultivated human
uveal melanoma cells: (a) Cultivated
melanoma cells. (b) Stained positively for
the ﬂuorescein isothiocyanate (FITC)-
conjugated Melan-A antibody (green). (c)
Note DAPI-stained melanoma cells nuclei
in blue color and (d) merged image (FITC-
labeled Melan-A and DAPI).
F I G . 4 . Light microscopy image of melanoma cells 24 h after
treatment with GNPs.
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equipment inaccuracy, human error, and other confounding factors,
contribute to the inconsistencies that may be observed between
experimental (in vitro) data and clinical calculation.
The main purpose of radiation therapy is to enhance the radia-
tion dose to the tumor while sparing the healthy tissue. Given the
radiation dose needed to halt the growth of choroidal melanoma in a
speciﬁc time interval, administration of GNPs would increase tumor
dose absorption. Increasing the radiation dose absorbed by the
tumor leads to an increase the number of dead cancer cells and a
decrease in treatment time. Furthermore, the radiation dose
absorbed by normal tissues will decrease as a result of decreased
treatment time.
GNPs cytotoxicity assays (Fig. 5) showed that GNP concentra-
tions of 50 and 100 lg/ml have no obvious cytotoxicity in mela-
noma cells, and the highest cytotoxicity was observed at a
concentration of 600 lg/ml.
Comparison of the results of melanoma and Burkitt’s lymphoma
cell cytotoxicity tests (Fig. 6) revealed that different concentrations
of GNPs do not have the same effect on cell viability in both cancer
cell types. Concentration of 200 lg/ml showed toxicity effects in
both melanoma and lymphoma cells however, in this concentration,
a slight decrease of about 25% in cell viability was observed in mela-
noma cells, whereas in Burkitt’s lymphoma cells, the same GNP con-
centration resulted in a >50% decrease in viability. A signiﬁcant
decrease in cell viability, of about 45% and 60%, was observed when
melanoma cells were incubated with 400 and 600 lg/ml GNPs, re-
spectively. In Burkitt’s lymphoma cells treated with 400 and 600 lg/
ml GNPs, the decrease in cell viability was more than 70% at both
concentrations. Therefore, cellular cytotoxicity responses are cell
type speciﬁc. Furthermore, our results show that GNPs in concentra-
tions lower than 100 lg/ml can be reliably incubated with choroidal
melanoma cells without causing visible cell damage.
F I G . 5 . Viability comparison of
melanoma cells exposed to different
concentrations of GNPs as an indicator of
GNPs toxicity in human eye melanoma
cells. Cell viability was measured by the
MTT assay test. Viability was calculated as
the percentage of the viable cells
compared to the untreated controls
(CONT). The error bars represent the
standard deviation of the mean of three
replicates.
F I G . 6 . Comparison of the cytotoxicity
induced by different concentrations of
GNPs in the melanoma and Burkitt’s
lymphoma cells on third day after
incubation. The error bars represent the
standard deviation of the mean of three
replicates.
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We observed about 8% and 12% increase in cell death in mela-
noma and Burkitt’s lymphoma cells, respectively, 7 days after irradia-
tion in the absence of GNPs, compared with untreated cells (Figs 7
and 8). Compared to controls (untreated cells), in the presence of 50,
100, and 200 lg/ml GNPs cell death increased by about 29%, 34%,
and 44%, respectively for melanoma cells and 36%, 41%, and 56%,
respectively for lymphoma cells (Fig. 8). While concentrations of 50
and 100 lg/ml GNPs alone have no obvious cytotoxic effects in
melanoma cells, cell metabolism was signiﬁcantly reduced when the
cells were exposed to irradiation.
Here, we performed cytotoxicity assays comparing ﬁve concen-
trations of GNPs in choroidal melanoma cells. Additionally, we com-
pared the combined effects of these GNP concentrations and three
irradiation doses on choroidal melanoma and Burkitt’s lymphoma
cells. Taken together these results shows that radiation therapy com-
bined with GNPs would need to be speciﬁcally tailored for each can-
cer type.
Considering the sensitivity of the human eye, determination of
more precise optimum concentrations for GNPs and irradiation
doses for choroidal melanoma treatment will require further studies
including more GNP concentrations and a wider range of irradiation
doses.
This work is a nonclinical preliminary study of the effects of
GNPs on melanoma cells and has been performed using gamma radi-
ation from a cobalt source. GNPs-loaded cancer cells have increased
radiosensitivity to iodine and palladium, common radiation sources
for ocular brachytherapy. Therefore, utilization of such sources in
the clinical study of the effects of GNPs in the treatment of eye
tumors would lead to more practical, precise, and reliable results for
choroidal melanoma treatment plans.
The focus of this work was choroidal melanoma and Burkitt’s
lymphoma tumors. We performed in vitro study and compared the
results to examine the effects of GNPs on the mentioned tumor
cells. However, two unresolved issues have necessitated performing
an in vivo study.
Firstly, given the main purpose of radiation therapy in cancer
treatment, an in vivo study will allow us to simultaneously study the
effects of GNPs on cancer cells and the nearby healthy tissues.
Secondly, delivery of NPs to target organs, or tissues, is com-
monly done via intravenous injection and tumors uptake the NPs via
the blood circulation. Previous studies have examined the radiosensi-
tivity of tumor cells in the presence of GNPs in prostate, skin mela-
noma, and liver tumors. Considering the location of the eye in the
body, compared to the location of these other tumor types, it may
F I G . 7 . Cell death analysis of 30 Gy
irradiated GNPs-loaded melanoma cells
with the cobalt source. Cell death assay
shows increase in apoptosis of melanoma
cells with increase in concentration of
GNPs. This assay shows the most effects
of GNPs on cell death in 600 lg/ml
concentration. The error bar represent the
standard deviation of the mean of three
replicates.
F I G . 8 . Comparison of the apoptosis for
melanoma and Burkitt’s lymphoma cells on
the seventh day after irradiation for 50,
100, and 200 lg/ml concentrations of
GNPs. The error bars represent the
standard deviation of the mean of three
replicates.
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be that a different method of GNPs delivery is required for eye
tumors. An in vivo study can provide the optimal conditions for
determining the most suitable way to deliver NPs into eye tumors.
The availability of an in vivo study of choroidal melanoma could
lead to a better understanding of the effects of GNPs in melanoma
dosimetry. A full experimental investigation of the effects of the
GNPs on brachytherapy dosimetry inside the choroidal melanoma
could answer many of the questions raised by this in vitro study.
Furthermore, such analyses lead to increased reliability of results and
more accurate pretreatment planning for GNPs-based choroidal
melanoma treatment.
Choroidal melanoma is structurally different from other cancer
cells in which the effects of GNPs have been studied. This is the ﬁrst
report of the effects of GNPs on radiotherapy of eye tumors and
this study was designed to physically evaluate the response of
GNPs-loaded melanoma cells to gamma irradiation.
The results showed that incubation of melanoma cells with
GNP concentrations lower than 100 lg/ml accompanied by
gamma irradiation considerably decreased cell viability. In the
absence of irradiation GNPs in such concentrations did not obvi-
ously affect the metabolism of cultured melanoma cells. The
decrease in cell viability was the result of a signiﬁcant increase in
absorbed energy by the tumor. Moreover, it was found that
concentrations of GNPs higher than 200 lg/ml induced obvious
cytotoxicity in melanoma cells.
Assays of GNPs cytotoxicity in Burkitt’s lymphoma cells showed
a slight decrease in cell viability at a concentration of 50 lg/ml and
clear cytotoxicity at concentrations higher than 100 lg/ml.
This study examined ﬁve different concentrations of GNPs. The
concentration and proper injection doses for GNPs in a sensitive tis-
sue, such as the human eye, are important variables that need to be
determined. However, further in vitro studies investigating various
different sizes and concentrations of GNPs are required to deter-
mine the optimum conditions before any clinical or in vivo research
can commence.
GNPs, combined with brachytherapy, are expected to be bene-
ﬁcial for ocular cancer patients. However, in vivo studies are nec-
essary to enable precise investigation of the effects of GNPs on
cancerous and healthy tissues to obtain reliable pretreatment plan-
ning for choroidal melanoma therapy. Therefore, future directions
should involve a full investigation of the effects of GNPs on the
choroidal melanoma dosimetry with a brachytherapy source in an
animal model.
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